Search research articles
Contact Us
Filters
Showing results (121-130 of 207) with videos related to
Page
of 21
Sort By:
Journal of the International Association of Providers of AIDS Care
|
October 19, 2019
Women of Reproductive Age Living with HIV in Argentina: Unique Challenges for Reengagement in Care
Diego Cecchini, Maria Luisa Alcaide, Violeta de Jesus Rodriguez, et al.
AIDS and Behavior
|
May 4, 2019
Suicidal Ideation Among Adults Re-engaging in HIV Care in Argentina
Lissa N Mandell, Violeta J Rodriguez, Aileen De La Rosa, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 24, 2019
Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety Analysis
Melanie Thompson, Chloe Orkin, Jean-Michel Molina, et al.
Memorias Do Instituto Oswaldo Cruz
|
March 7, 2025
Pharmacokinetics of two pharmaceutical presentations of benznidazole in adult Trypanosoma cruzi infected population
Yolanda Hernández, María Elena Marson, Marisa Liliana Fernández, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 20, 2006
Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial
Pedro Cahn, Jorge Villacian, Adriano Lazzarin, et al.
AIDS (London, England)
|
August 2, 2013
Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria
Bohdan Nosyk, Bertrand Audoin, Chris Beyrer, et al.
Plos One
|
September 7, 2019
Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trial
Darrell H S Tan, Maria Jose Rolon, Maria Ines Figueroa, et al.
The Lancet. Infectious Diseases
|
May 3, 2014
Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial
Pedro Cahn, Jaime Andrade-Villanueva, José R Arribas, et al.
AIDS (London, England)
|
August 30, 2008
Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents
Juan C Salazar, Pedro Cahn, Ram Yogev, et al.
Plos One
|
June 4, 2011
Cross-sectional analysis of late HAART initiation in Latin America and the Caribbean: late testers and late presenters
Brenda Crabtree-Ramírez, Yanink Caro-Vega, Bryan E Shepherd, et al.
Page
of 21
Search research articles
Search
Showing results (121-130 of 207) with videos related to
Sort By:
Page
of 21
Journal of the International Association of Providers of AIDS Care
|
October 19, 2019
Women of Reproductive Age Living with HIV in Argentina: Unique Challenges for Reengagement in Care
Diego Cecchini, Maria Luisa Alcaide, Violeta de Jesus Rodriguez, et al.
AIDS and Behavior
|
May 4, 2019
Suicidal Ideation Among Adults Re-engaging in HIV Care in Argentina
Lissa N Mandell, Violeta J Rodriguez, Aileen De La Rosa, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 24, 2019
Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety Analysis
Melanie Thompson, Chloe Orkin, Jean-Michel Molina, et al.
Memorias Do Instituto Oswaldo Cruz
|
March 7, 2025
Pharmacokinetics of two pharmaceutical presentations of benznidazole in adult Trypanosoma cruzi infected population
Yolanda Hernández, María Elena Marson, Marisa Liliana Fernández, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 20, 2006
Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial
Pedro Cahn, Jorge Villacian, Adriano Lazzarin, et al.
AIDS (London, England)
|
August 2, 2013
Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria
Bohdan Nosyk, Bertrand Audoin, Chris Beyrer, et al.
Plos One
|
September 7, 2019
Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trial
Darrell H S Tan, Maria Jose Rolon, Maria Ines Figueroa, et al.
The Lancet. Infectious Diseases
|
May 3, 2014
Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial
Pedro Cahn, Jaime Andrade-Villanueva, José R Arribas, et al.
AIDS (London, England)
|
August 30, 2008
Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents
Juan C Salazar, Pedro Cahn, Ram Yogev, et al.
Plos One
|
June 4, 2011
Cross-sectional analysis of late HAART initiation in Latin America and the Caribbean: late testers and late presenters
Brenda Crabtree-Ramírez, Yanink Caro-Vega, Bryan E Shepherd, et al.
Page
of 21